For those who like patterns, biotech names’ growth stories tend to look remarkably similar. These stocks are less reliant on earnings reports and …
Sarepta shares dropped 4% after patient deaths revealed in the FDA FAERS database.
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
This hedge fund guru has made the right call on these three booming stocks.
Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring nearly 18% in pre-market trading Thursday, after the drug maker reported solid second-quarter earnings and provided a …
In the biotech-verse, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is riding a fresh wave of positive momentum following first quarter earnings that outclassed investors’ …
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the first quarter of 2017. “The first quarter of 2017 showed significant progress across all …
Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), as it appears that payors are still actively …
Wells Fargo and Needham are chiming in with mixed takes on biotech companies Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Sarepta Therapeutics Inc (NASDAQ:SRPT). …